
|Articles|February 1, 2004
Filler era offers new options, challenges
Waikoloa, Hawaii - The U.S. Food and Drug Administration's recent approval of the cosmetic dermal filler Restylane (Medicis) indicates the beginning of a new phase for dermatologists due to the enhanced benefits it offers patients, according to Mark G. Rubin, M.D.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
3
ICYMI: First Patient Dosed in Global Phase 2 Study of Oral TYK2 Inhibitor Soficitinib for PN
4
Dermatology Conferences and Meetings Calendar: December 2025
5


















